简体
  • 简体中文
  • 繁体中文

热门资讯> 正文

Dr. Reddy's Laboratories' Atomoxetine Hydrochloride Capsules Suspended in China

2024-09-03 22:06

10:06 AM EDT, 09/03/2024 (MT Newswires) -- Dr. Reddy's Laboratories (RDY) said in a regulatory filing Tuesday that China's National Medical Products Administration has issued an order suspending the import, sale, and use of the company's atomoxetine hydrochloride capsules, effective Aug. 30, for failing to meet the country's good manufacturing practice standards.

China's National Drug Joint Procurement Office has also issued an order to put the company on a "violation list", Dr. Reddy's said, adding the move suspends its eligibility to participate in drug procurement activities in the country starting Aug. 30 until Feb. 28, 2026.

Dr. Reddy's said it's in the process of determining the financial impact of the orders.

The company's shares were falling 2% in recent trading.

Price: 81.80, Change: -1.67, Percent Change: -2.00

风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。